5-甲基苯并[b]噻吩-3-乙酸 | 1735-12-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 5-甲基苯并[b]噻吩-3-乙酸
• 英文名称: 5-methylbenzo[b]thiophene-3-acetic acid
• 英文别名: 2-(5-Methyl-1-benzothiophen-3-yl)acetic acid
• CAS: 1735-12-2
• 化学式: C₁₁H₁₀O₂S
• mdl: MFCD01663450
• 分子量: 206.265
• InChiKey: KYZMXUFJGWTSOX-UHFFFAOYSA-N

物化性质

• 熔点：
  111-112 °C
• 沸点：
  390.8±27.0 °C(Predicted)
• 密度：
  1.315±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  5-甲基苯并[b]噻吩-3-乙酸 在 三氟化硼乙醚 、 碳酸氢钠 、 一水合肼 、 N,N'-二环己基碳二亚胺 、 sodium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 6.0h， 生成 2-amino-6-methyl[1]benzothieno[2,3-c]pyridin-3(2H)-one
  参考文献：
  名称：

  Condensed Diazepines. Synthesis of 1-R-3,4-Dihydro-5H-Benzothieno[2,3-d][1,2]Diazepin-4-Ones

  摘要：

  Novel 1-R-3,4-dihydro-5H-benzothieno[2,3-d][1,2]diazepin-4-ones have been prepared by the cyclization of 2-acyl(aroyl)benzo[b]thiophene-3-acetic acids or 1-R-benzothieno[2,3-c]pyr-3-ones with hydrazine hydrate.

  DOI：

  10.1007/s10593-012-1146-4
• 作为产物：
  描述：

  4-甲苯硫酚 在 sodium hydroxide 、 PPA 作用下， 以 吡啶 、 水 、 氯苯 为溶剂， 反应 6.75h， 生成 5-甲基苯并[b]噻吩-3-乙酸
  参考文献：
  名称：

  Tominaga, Yoshinori; Pratap, Ram; Castle, Raymond N., Journal of Heterocyclic Chemistry, 1982, vol. 19, p. 859 - 863

  摘要：

  DOI：

文献信息

• 2-Aminomethyl piperidines as novel urotensin-II receptor antagonists
  作者：Jian Jin、Yonghui Wang、Feng Wang、Dongchuan Shi、Karl F. Erhard、Zining Wu、Brian F. Guida、Sarah K. Lawrence、David J. Behm、Jyoti Disa、Kalindi S. Vaidya、Christopher Evans、Lynette J. McMillan、Ralph A. Rivero、Michael J. Neeb、Stephen A. Douglas

  DOI：10.1016/j.bmcl.2008.03.078

  日期：2008.5

  A series of 2-aminomethyl piperidines has been discovered as novel urotensin-II receptor antagonists. The synthesis, initial structure-activity relationships, and optimization of the initial hit that resulted in the identification of potent, cross-species active, and functional urotensin-II receptor antagonists such as 1a and 11a are described.

  已经发现了一系列2-氨基甲基哌啶作为新型尿素-II受体拮抗剂。描述了合成，初始结构-活性关系以及初始命中的优化，从而确定了有效的，跨物种活性和功能性尿紧张素-II受体拮抗剂，例如1a和11a。
• Photocyclization of 2-[1]benzothien-3-yl)-3-phenylpropenoic acids
  作者：Yoshinori Tominaga、Lyle W. Castle、Raymond N. Castle

  DOI：10.1002/jhet.5570330452

  日期：1996.7

  Photocyclization of the substituted 2-([1]benzothien-3-yl)-3-phenylpropenoic acids 3a-c in the presence of iodine and air in a benzene-cyclohexane mixture afforded a separable mixture of three compounds, benzo[b]naphtho[2,1-d]thiophene-6-carboxylic acids 4a-c, 6H-benzo[b]naphtho[2,3-d]thiopyran-6-ones 5a-c, and 10-methoxy-2-methyl-6H-benzo[b]naphtho[2,3-d]pyran-6-one (6).

  在苯和环己烷混合物中，在碘和空气存在下，将取代的2-（[1]苯并噻吩-3-基）-3-苯基丙酸3a-c光环化，得到三种化合物苯并[ b ]萘的可分离混合物[2,1 - d ]噻吩-6-羧酸4a-c，6 H-苯并[ b ]萘并[2,3 - d ]噻喃-6-酮5a-c和10-甲氧基-2-甲基- 6 H-苯并[ b ]萘并[2,3 - d ]吡喃-6-一（6）。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC AND INFLAMMATORY DISEASES
  申请人：Sanière Laurent Raymond Maurice

  公开号：US20130303515A1

  公开（公告）日：2013-11-14

  Compounds are disclosed that have a formula represented by the following: These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example inflammatory conditions, infectious diseases, autoimmune diseases, diseases involving impairment of immune cell functions, cardiometabolic diseases, and/or proliferative diseases.

  公开了具有以下式子表示的化合物：这些化合物可以制备成药物组合物，并可用于哺乳动物，包括人类的预防和治疗，例如炎症性疾病、传染病、自身免疫疾病、涉及免疫细胞功能受损的疾病、心脏代谢疾病和/或增殖性疾病等。
• Substituted trans-1.2-diaminocyclohexyl amide compounds
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0147085A2

  公开（公告）日：1985-07-03

  Substituted trans-1,2-diaminocyclohexyl amide compounds demonstrating selective opioid receptor binding possess utility as analgesic, diuretic, and psychotherapeutic agents. A method of preparing the compounds, pharmaceutical compositions employing the compounds, and a method of alleviating pain employing the compounds are also disclosed.

  公开了具有选择性阿片受体结合作用的取代反式-1,2-二氨基环己基酰胺化合物，可用作镇痛剂、利尿剂和精神治疗剂。 还公开了制备这些化合物的方法、使用这些化合物的药物组合物以及使用这些化合物减轻疼痛的方法。

表征谱图